Related Experiment Videos
[Multimodality therapy concepts in stomach carcinoma].
H J Meyer1, H R Zachert, G J Opitz
1Klinik für Allgemein- u. Viszeralchirurgie, Städt. Klinikum Solingen, Gotenstrasse 1, 42653 Solingen.
Kongressband. Deutsche Gesellschaft Fur Chirurgie. Kongress
|February 5, 2002
Summary
Gastric cancer survival remains poor despite surgery. Multimodality treatments like neoadjuvant chemotherapy show promise but require further research for better response prediction and improved patient outcomes.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Gastric cancer prognosis is poor even after R0 resection.
- Multimodality treatments, including neoadjuvant chemotherapy, are being investigated to improve outcomes.
- Current neoadjuvant chemotherapy approaches are considered experimental.
Purpose of the Study:
- To evaluate the efficacy of various multimodality treatments for gastric cancer.
- To explore strategies for improving response prediction and evaluation in gastric cancer treatment.
- To assess the impact of intraoperative and adjuvant therapies on survival rates.
Main Methods:
- Review of phase II/III studies on preoperative chemotherapy for gastric cancer.
- Analysis of intraoperative radio- or intraperitoneal chemotherapy effects.
- Evaluation of adjuvant (immuno-)chemotherapy and chemo-/radiotherapy studies.
Main Results:
- Some positive results from neoadjuvant chemotherapy have been observed.
- Intraoperative therapies may reduce regional relapse but not general survival.
- Adjuvant (immuno-)chemotherapy and chemo-/radiotherapy show potential survival benefits, especially in node-positive patients.
Conclusions:
- Neoadjuvant chemotherapy requires more precise response evaluation.
- Adjuvant therapies, particularly in node-positive patients, demonstrate survival benefits.
- Further uniform prospective studies are essential to optimize multimodality treatment strategies for gastric cancer.